Humalog

Humalog is a brand name for insulin lispro, a rapid-acting insulin analog used to improve glycemic control in people with diabetes mellitus. Developed by Eli Lilly, it was approved for medical use in the United States in 1996. Lispro differs from human insulin by swapping two amino acids at positions B28 and B29, which accelerates absorption after subcutaneous injection.

Use and administration: Humalog is delivered by subcutaneous injection or via an insulin pump to provide mealtime bolus doses or to correct hyperglycemia. It is usually given within 15 minutes before meals or immediately after starting a meal, depending on regimen. When used in intensive regimens, it is typically part of a basal-bolus plan with a longer-acting insulin. It is not intended for routine intravenous use outside hospital settings, where specially prepared insulin is used under supervision.

Pharmacokinetics: Onset of action is about 15 minutes, with peak activity around 1–2 hours, and a duration of roughly 3–5 hours, though these times vary by dose, injection site, and individual factors.

Formulations: Humalog is available as a rapid-acting U-100 solution for vials and prefilled pens, and a concentrated U-200 version for patients needing larger doses. Premixed formulations, Humalog Mix 50/50 and 75/25, combine lispro with lispro protamine suspension (intermediate-acting) for simplified regimens.

Safety and storage: Dosing is individualized; common adverse effects include hypoglycemia, allergic reactions, lipodystrophy at injection sites, and edema. Store unopened vials or pens refrigerated (2–8°C). After first use, vials or pens may be stored at room temperature for up to about 28 days, away from heat and light. Insulin lispro is used under medical supervision in pregnancy when clinically indicated.